PharmDr. Hana Jansová, PhD.

Born: December 9, 1986, Ústí nad Orlicí, Czech Republic.

 

Education, Academic and Scientific Degrees:

2016 – PhD. in Pathobiochemistry and Xenobiochemistry (FPharm HK)

2016 – PharmDr. (FPharm HK)

2011 – MSc. in Pharmacy (FPharm HK)

Working Experience:

Since 2011 – teaching and research assistant in Department of Biochemical Sciences (FPharm HK)

Research Interests

Cardiotoxicity; oxidative stress; iron chelators, dexrazoxane and its derivates as potential cardioprotectants; in vitro studies

Teaching

Since 2011 – teaching of practical exercises from General Biochemistry

Since 2015 – share in conducting of several diploma theses

Memberships in Scientific Societies:

Since 2014 – membership in Czech Society for Clinical and Experimental Pharmacology and Toxicology

Awards

2014    – Award (1st place) of the Czech Society for Clinical and Experimental Pharmacology and Toxicology for best publication of the year of young authors (category of Toxicology)

2010 – 3rd place in Transnational Student Scientific Conference in Biological science section (Prague)

2010 – 1st place in Student Scientific Conference of Faculty of Pharmacy UK in Biological science section (Hradec Králové)

Peer Review

Master thesis (1/FaF), Bachelor thesis – (1/FaF).

Grant Projects

As a principal investigator (1): GA UK (Study of cardioprotective effects of novel aroylhydrazone prochelators of iron that are activated by oxidative stress)

As a co-investigator (10x): GA ČR (1x), GA UK (2x), grant Czech Society of Cardiology (1x), IGA MZ (1x), UNCE (1x)

Publications and Citations (in total):

Number of publications in WoS/Scopus: 13/13, all with IF

Number of citations in WoS/Scopus – total 73/79, without self-citations 58/64

H-index in WoS/Scopus (with self-citations) = 5/6

Summary of Publications (in last 5 years, 2012-2017):

in WoS/Scopus: 13/13, cumulative IF (summa IF) = 48.336, average IF = 3.718.

Summary of all publications:

1.         Lencova-Popelova O, Jirkovsky E, Jansova H, Jirkovska-Vavrova A, Vostatkova-Tichotova L, Mazurova Y, Adamcova M, Chladek J, Hroch M, Pokorna Z, Gersl V, Simunek T and Sterba M. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. J Mol Cell Cardiol. 2016;91:92-103. (IF 2016: 5.680) (Q1)

2.         Lencova-Popelova O, Jansova H, Jirkovsky E, Bures J, Jirkovska-Vavrova A, Mazurova Y, Reimerova P, Vostatkova L, Adamcova M, Hroch M, Pokorna Z, Kovarikova P, Simunek T and Sterba M. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Toxicology. 2016;372:52-63. (IF 2016: 3.582) (Q1)

3.         Jansova H, Bures J, Machacek M, Haskova P, Jirkovska A, Roh J, Wang Q, Franz KJ, Kovarikova P and Simunek T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology. 2016;350-352:15-24. (IF 2016: 3.582) (Q1)

4.         Haskova P, Jansova H, Bures J, Machacek M, Jirkovska A, Franz KJ, Kovarikova P and Simunek T. Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology. 2016;371:17-28. (IF 2016: 3.582) (Q1)

5.         Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR and Kovarikova P. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget. 2015;6:42411-28. (IF 2015: 5.008) (Q1)

6.         Potuckova E, Roh J, Machacek M, Sahni S, Stariat J, Sestak V, Jansova H, Haskova P, Jirkovska A, Vavrova K, Kovarikova P, Kalinowski DS, Richardson DR and Simunek T. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS One. 2015;10:e0139929. (IF 2015: 3.057) (Q1)

7.         Jirkovska-Vavrova A, Roh J, Lencova-Popelova O, Jirkovsky E, Hruskova K, Potuckova-Mackova E, Jansova H, Haskova P, Martinkova P, Eisner T, Kratochvil M, Sus J, Machacek M, Vostatkova-Tichotova L, Gersl V, Kalinowski DS, Muller MT, Richardson DR, Vavrova K, Sterba M and Simunek T. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research. 2015;4:1098-1114. (IF 2015: 2.161)

8.         Bureš J, Jansová H, Stariat J, Filipský T, Mladěnka P, Šimůnek T, Kučera R, Klimeš J, Wang Q, Franz KJ and Kovaříková P. LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). J Pharm Biomed Anal. 2015;105:55-63. (IF 2015: 2.979) (Q1)

9.         Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K and Šimůnek T. Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. PLoS One. 2014;9:e112059. (IF 2014: 3.234) (Q1)

10.       Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR and Simunek T. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS One. 2014;9:e88754. (IF 2014: 3.234) (Q1)

11.       Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ and Simůnek T. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radic Biol Med. 2014;74:210-21. (IF 2014: 5.736) (Q1)

12.       Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M and Simunek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One. 2013;8:e76676. (IF 2013: 3.534) (Q1)

13.       Macková E, Hrušková K, Bendová P, Vávrová A, Jansová H, Hašková P, Kovaříková P, Vávrová K and Simůnek T. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. Chemico-biological interactions. 2012;197:69-79. (IF 2012: 2.967)

© 2017 Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico